There were 1,442 press releases posted in the last 24 hours and 405,479 in the last 365 days.

ELBIT IMAGING LTD. ANNOUNCES ADDITIONAL BUYBACK OF NOTES SERIES I

Tel Aviv, Israel, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today, further to its press releases dated July 18, 2018, October 11, 2018, October 18, 2018, October 25, 2018 and November 8, 2018, regarding a new Buy-Back plan for its (Series I) notes (the “Notes” and the "Current Buy-Back Plan", respectively), that it completed repurchases of additional 387,506 par value Notes.

Below is a table containing a summary of data regarding the repurchase of Notes under the Current Buy-Back Plan:

Note The acquiring corporation Quantity purchased (Par value) Weighted average price Total amount paid(NIS)
Series I Elbit Imaging Ltd 31,664,887 127.8922 40,496,934

Since the issuance of the Notes (in February 2014) and until the date of this press release, the Company has published two (2) buy-back plans for the repurchase of up to NIS 120 million of Notes. As of the date of this press release, the Company has purchased par value NIS 73.9 million Notes for a total cash consideration of NIS 89.7 million.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) land in India which is designated for sale (and which was initially designated for residential projects); and (iii) land in Eastern Europe which is designated for sale (and which was initially designated for development of commercial centers).

For Further Information:
Company Contact
Ron Hadassi
CEO and Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com

Elbit Logo.jpg

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.